GlassScriptPhysician profile
Arthur W Hall
NPI 1750772190
$3,991.18
in general payments reported to CMS, 2019-2025
27 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $17.73 · 2023: $1,017 · 2024: $1,025 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185 · Education: $48.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.28 |
| Education | $48.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $550.69 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate II, Lvas Implant Kit, Heartmate Touch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.90 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $410.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.72 | 2021-2025 | Wainua, Farxiga |
| Pfizer INC. | $307.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $266.57 | 2023-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $263.92 | 2021-2025 | Onpattro, Amvuttra |
| Actelion Pharmaceuticals US, INC. | $250.39 | 2023-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $191.90 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Bridgebio Pharma, INC. | $139.16 | 2025 | Attruby |
| Daxor Corporation | $115.78 | 2025 | Bva-100 |
| Cvrx, INC. | $98.98 | 2024-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $86.30 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.29 | 2021-2025 | Lifevest |
| Medtronic, INC. | $84.42 | 2024 | Intellis Adaptivestim, Vitalflow Console |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Briohealth Solutions, INC. | $77.03 | 2024 | Briovad |
| E.R. Squibb & Sons, L.L.C. | $63.01 | 2025 | Camzyos |
| Novo Nordisk INC | $48.63 | 2024-2025 | Wegovy |
| Scpharmaceuticals INC. | $39.04 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.61 | 2021-2025 | |
| Astellas Pharma US INC | $24.22 | 2021 | |
| Abiomed | $22.81 | 2024 | Impella |
| Sandoz INC. | $21.52 | 2023 | Treprostinil |
| Irhythm Technologies, INC. | $19.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.03 | 2023 | Xarelto |
| Amgen INC. | $13.47 | 2025 | Repatha |
| Medline Industries LP | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.